---
schema_version: "secwatch.filing_event.v1"
accession: "0001178913-25-002333"
form_type: "8-K"
ticker: "SLXN"
cik: "0002022416"
company_name: "Silexion Therapeutics Corp"
filed_at: "2025-07-08T23:59:59+00:00"
generated_at: "2026-05-18T09:09:22.051471+00:00"
event_type: "regulatory"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Silexion Therapeutics wins Nasdaq hearing to stay listed; transfer to Capital Market with equity conditions

## Summary
- Nasdaq panel granted continued listing subject to achieving $2.5M shareholders' equity by Sept 19, 2025.
- Shares and warrants transfer from Global Market to Nasdaq Capital Market effective July 8, 2025, under same symbols.
- To cure potential bid price deficiency, company plans 1-for-15 reverse share split after shareholder meeting on July 14, 2025.

## SEC filing metadata
- accession: 0001178913-25-002333
- form_type: 8-K
- ticker: SLXN
- cik: 0002022416
- company_name: Silexion Therapeutics Corp
- filed_at: 2025-07-08T23:59:59+00:00
- event_type: regulatory
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2022416/000117891325002333/0001178913-25-002333-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2022416/000117891325002333/zk2533425.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001178913-25-002333
- JSON: https://secwatch.observer/filing/0001178913-25-002333.json
- Plain text: https://secwatch.observer/filing/0001178913-25-002333.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.